The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

NCT03097120 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

309

Enrollment

OTHER

Sponsor class

Conditions

Heart Disease

Interventions

DRUG: 0.625 mg of conjugated equine estrogen
DRUG: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
DRUG: placebo tablets

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]